Core Viewpoint - Chongqing Mountain Outside Blood Purification Technology Co., Ltd. (referred to as "Mountain Outside") expects significant growth in net profit for the year 2025, with projections indicating an increase of 98% to 125% year-on-year [1] Group 1: Financial Performance - The company anticipates a net profit attributable to shareholders of the parent company between 140 million to 159 million yuan for 2025, representing a substantial year-on-year growth [1] - The expected net profit after deducting non-recurring gains and losses is projected to be between 134 million to 154 million yuan, reflecting a year-on-year increase of 135% to 170% [1] Group 2: Business Operations - Mountain Outside specializes in the research, production, and sales of blood purification equipment and consumables, as well as providing chain dialysis medical services [1] - The company has developed key technologies for blood purification equipment, including Continuous Renal Replacement Therapy (CRRT) devices, dialysis machines, and blood perfusion machines, along with various consumables [1] - The company's products are widely used in treating various conditions such as acute and chronic renal failure, uremia, multiple organ failure, and poisoning [1] Group 3: Market Position and Growth - As a leading domestic blood purification equipment manufacturer, Mountain Outside has seen a continuous increase in market share due to its technological advantages and strong brand effect [2] - The sales revenue from self-produced blood purification consumables has also significantly increased, contributing to overall revenue growth [2] - With the increase in production and sales volume, the fixed costs of self-produced consumables have decreased, leading to improved gross margins and enhanced overall profitability [2]

Core Viewpoint - The company, Shanwaishan, has experienced significant fluctuations in revenue and net profit since its listing over two years ago, with a notable decline in 2024. Financial Performance - In 2023, Shanwaishan achieved a revenue of 690 million yuan, representing a year-on-year increase of 80.65%, and a net profit of 195 million yuan, up 228.34% [2] - However, in 2024, the company reported a revenue of 567 million yuan, a year-on-year decrease of 17.80%, and a net profit of 71 million yuan, down 63.55% [2][3] Reasons for Performance Decline - The decline in performance is attributed to the impact of the "critical care capacity building policy," which led to high sales of high-margin continuous renal replacement therapy (CRRT) devices in 2023. Excluding this one-time effect, revenue in 2024 would have increased by 18.04% year-on-year [2] - Additionally, the company increased its R&D investment by 42.62% during the reporting period, which negatively affected profits. In 2024, R&D expenditure was 54.24 million yuan, up from 38.03 million yuan in 2023, while net profit decreased by 124 million yuan compared to the previous year [3] Shareholder Actions - On May 8, 2024, two shareholders announced a plan to reduce their holdings by up to 4% of the total share capital due to personal funding needs [3] - Since 2024, multiple shareholders have engaged in "queue-style" reductions, with some executing "clearance-style" sell-offs. For instance, in January 2024, shareholders Zhuhai Xiuheng and Huagai Xincheng sold shares at prices around 25.25 yuan per share, realizing approximately 163 million yuan and 2.13 million yuan, respectively [4] - In February 2025, another shareholder, Zhuhai Xiuheng, planned to reduce its holdings by up to 9.38 million shares, representing 2.92% of the total share capital [5] Founder Actions - In contrast to the trend of shareholder reductions, the founder and chairman, Gao Guangyong, has increased his stake in the company, purchasing shares in July 2023 for a total of approximately 840,000 yuan, despite the stock price declining to 12.97 yuan by May 14, 2024 [6]